Journal: Infection and Immunity
Article Title: Rickettsia rickettsii inactivated whole cell antigen vaccine protects against Rocky Mountain spotted fever independent of the adjuvant used
doi: 10.1128/iai.00412-25
Figure Lengend Snippet: Development of antibodies by vaccinated dogs. Plasma samples collected from all dogs several days following vaccinations and infection challenges were assessed by ELISA for the presence of R. rickettsii -specific IgG ( A ), IgG1 ( B ), and IgG2 ( C ). All dogs receiving WCAV developed antigen-specific IgG responses following the primary vaccination, which increased following the booster vaccination. R. rickettsii -specific total IgG and IgG subclass; IgG1 and IgG2 in different groups of vaccinated dogs were compared by two-way ANOVA test followed by multiplicity-adjusted post hoc comparisons (Tukey). P -value < 0.05 was considered statistically significant, which was observed for total IgG and IgG 2 for Quil A compared to Montanide and Alhydrogel from day 37 onward with P -values of ≤0.0001. Vertical dotted blue lines refer to the days of booster vaccination.
Article Snippet: One hundred microliters of a 1:50,000 dilution of anti-canine total IgG (PA1-29738, ThermoFisher, USA), 1:10,000 anti IgG1 (AHP947P, Bio-Rad, Hercules, CA, USA), or 1:5,000 of anti IgG2 (AHP948P, Bio-Rad, Hercules, CA, USA) peroxidase-labeled antibodies was added to each well, and plates were incubated for 45 min at 37°C.
Techniques: Clinical Proteomics, Infection, Enzyme-linked Immunosorbent Assay